Press Releases Items Per Page 102550 Year None20222021202020192018201720162015201420132012201120102007 10.29.18 Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018 10.25.18 Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer 09.26.18 Syndax to Present at the 2018 Cantor Global Healthcare Conference 09.25.18 Syndax Announces Changes to its Board of Directors 09.24.18 Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer 09.05.18 Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer 08.28.18 Syndax Announces Participation at Three Upcoming Investor Conferences 08.07.18 Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update 07.31.18 Syndax to Announce Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018 05.30.18 Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration 05.30.18 Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences 05.17.18 Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »
10.29.18 Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018
10.25.18 Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer
09.24.18 Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
09.05.18 Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer
08.07.18 Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update
07.31.18 Syndax to Announce Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
05.17.18 Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)
